icon for FDA批準阿斯利康的Truqap （ capivasertib ）？

FDA批準阿斯利康的Truqap （ capivasertib ）？

Ended: 4月 30

Ended: 4月 30

是

<1% 機率

$6,942 交易量

$6,942 交易量

2026-04-30

是

<1% 機率

$6,942 交易量

$6,942 交易量

2026-04-30

As of market creation, the FDA's expected decision date for the specified application is April 30, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Truqap (capivasertib) as a treatment for metastatic hormone-sensitive prostate cancer (PTEN-deficient) by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

市場開放時間： Apr 20, 2026, 5:45 PM ET

交易量

$6,942

結束日期

2026-04-30

市場開放時間

Apr 20, 2026, 5:45 PM ET

Resolver

As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Truqap (capivasertib) as a treatment for metastatic hormone-sensitive prostate cancer (PTEN-deficient) by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

已提議結果: 否

無爭議

最終結果: 否

As of market creation, the FDA's expected decision date for the specified application is April 30, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Truqap (capivasertib) as a treatment for metastatic hormone-sensitive prostate cancer (PTEN-deficient) by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

交易量

$6,942

結束日期

2026-04-30

市場開放時間

Apr 20, 2026, 5:45 PM ET

Resolver

As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Truqap (capivasertib) as a treatment for metastatic hormone-sensitive prostate cancer (PTEN-deficient) by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

已提議結果: 否

無爭議

最終結果: 否

警惕外部連結哦。

警惕外部連結哦。

Frequently Asked Questions

"FDA批準阿斯利康的Truqap （ capivasertib ）？" is a prediction market on Polymarket with 2 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "美國食品藥品監督管理局（FDA）批准阿斯利康的Truqap（capivasertib）了嗎？" at 0%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 0¢ implies that the market collectively assigns a 0% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"FDA批準阿斯利康的Truqap （ capivasertib ）？" is a newly created market on Polymarket, launched on Apr 20, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "FDA批準阿斯利康的Truqap （ capivasertib ）？," browse the 2 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

This is a wide-open market. The current leader for "FDA批準阿斯利康的Truqap （ capivasertib ）？" is "美國食品藥品監督管理局（FDA）批准阿斯利康的Truqap（capivasertib）了嗎？" at just 0%. With no outcome commanding a strong majority, traders see this as highly uncertain, which can present unique trading opportunities. These odds update in real-time, so bookmark this page to watch how the probabilities evolve.

The resolution rules for "FDA批準阿斯利康的Truqap （ capivasertib ）？" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.

Yes. You don't need to trade to stay informed. This page serves as a live tracker for "FDA批準阿斯利康的Truqap （ capivasertib ）？." The outcome probabilities update in real-time as new trades come in. You can bookmark this page and check the comments section to see what other traders are saying. You can also use the time-range filters on the chart to see how the odds have shifted over time. It's a free, real-time window into what the market expects to happen.

Polymarket odds are set by real traders putting real money behind their beliefs, which tends to surface accurate predictions. “FDA批準阿斯利康的Truqap （ capivasertib ）？” is still building its trading base, so the odds will become increasingly reliable as more participants enter the market. Prediction markets like Polymarket have a strong track record of accuracy, especially as events approach their resolution date. For example, Polymarket has a one month accuracy score of 94%. For the latest stats on Polymarket’s prediction accuracy, visit the accuracy page on Polymarket.

To place your first trade on "FDA批準阿斯利康的Truqap （ capivasertib ）？," sign up for a free Polymarket account and fund it using crypto, a credit or debit card, or a bank transfer. Once your account is funded, return to this page, select the outcome you want to trade, enter your amount, and click "Trade." If you're new to prediction markets, click the "How it works" link at the top of any Polymarket page for a quick step-by-step walkthrough of how trading works.

On Polymarket, the price of each outcome represents the market's implied probability. A price of 0¢ for "美國食品藥品監督管理局（FDA）批准阿斯利康的Truqap（capivasertib）了嗎？" in the "FDA批準阿斯利康的Truqap （ capivasertib ）？" market means traders collectively believe there is roughly a 0% chance that "美國食品藥品監督管理局（FDA）批准阿斯利康的Truqap（capivasertib）了嗎？" will be the correct result. If you buy "Yes" shares at 0¢ and the outcome is correct, you receive $1.00 per share — a profit of 100¢ per share. If incorrect, those shares are worth $0.

The "FDA批準阿斯利康的Truqap （ capivasertib ）？" market has been resolved. The final result has been determined and the market is no longer open for trading. You can still review the historical odds, outcome probabilities, and comments on this page to see how predictions evolved over time.

The "FDA批準阿斯利康的Truqap （ capivasertib ）？" market has an active community of 39 comments where traders share their analysis, debate outcomes, and discuss breaking developments. Scroll down to the comments section below to read what other participants think. You can also filter by "Top Holders" to see what the market's biggest traders are positioned on, or check the "Activity" tab for a real-time feed of trades.

Polymarket is the world's largest prediction market, where you can stay informed and profit from your knowledge of real-world events. Traders buy and sell shares on outcomes for topics ranging from politics and elections to crypto, finance, sports, tech, and culture, including markets like "FDA批準阿斯利康的Truqap （ capivasertib ）？." Prices reflect real-time, crowd-sourced probabilities backed by financial conviction, often providing faster and more accurate signals than polls, pundits, or traditional surveys.